MedTrace Logo

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

NCT00174993 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4373

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.

DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months

Sponsors & Collaborators

Principal Investigators

  • European Development Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Sweden
  • Switzerland
  • United Kingdom

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174993 on ClinicalTrials.gov